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Abstract
Background: Identification of biomarkers predicting therapeutic outcome of antidepressant treatment is one of the most 
important tasks in current research because it may transform the lengthy process of finding the right treatment for a given 
individual with depression. In the current study, we explored the potential of pretreatment pregenual anterior cingulate 
cortex activity as a putative biomarker of treatment response.
Methods: Thirty-two medication-free patients with depression were treated for 6 weeks with a selective serotonin reuptake 
inhibitor, escitalopram. Before treatment began, patients underwent an fMRI scan testing response to brief, masked, 
presentations of facial expression depicting sadness and happiness.
Results: After 6 weeks of treatment, there were 20 selective serotonin reuptake inhibitor responders and 12 nonresponders. 
Increased pretreatment pregenual anterior cingulate cortex activity to sad vs happy faces was observed in responders relative 
to nonresponders. A  leave-one-out analysis suggested that activity in the anterior cingulate cortex was able to predict 
response status at the level of the individual participant.
Conclusions: The study supports the notion of pregenual anterior cingulate cortex as a promising predictor of antidepressant 
response.
Keywords: anterior cingulate cortex, depression, selective serotonin reuptake inhibitors, treatment response prediction, 
functional magnetic resonance imaging
Introduction
The search for biomarkers that can predict clinical response 
to the pharmacotherapy of depression is a task of substantial 
practical importance. Only 50% of patients respond to the first 
treatment they try, and remission rates are even lower (around 
30%) (Rush et al., 2009). Many patients will take 2 or more dif-
ferent antidepressants before finding a drug that works for 
them (Warden et  al., 2007). Identifying patients unlikely to 
respond to first-line treatment may speed up the application 
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of second-line or adjunct treatments and improve overall time 
to remission.
Studies employing neuroimaging have led to the identifica-
tion of a number of candidates for treatment response predic-
tion biomarkers (e.g., McGrath et al., 2013; Dunlop et al. 2017). 
One of the best established is increased pretreatment activity 
in the pregenual anterior cingulate cortex (pgACC), which has 
been linked to a positive therapeutic response to antidepres-
sant treatments. In a review of 23 imaging studies, Pizzagalli 
(2011) concluded that increased activity in the rostral anterior 
cingulate cortex (ACC) (equivalent to pgACC) both in the rest-
ing state and in response to simple cognitive tasks was associ-
ated with positive outcome to a variety of treatment modalities, 
including pharmacotherapy, transcranial magnetic stimulation, 
and sleep deprivation. This was also shown in a meta-analysis 
by Fu et al. (2013).
Of the studies reviewed by Pizzagalli (2011) and Fu (2013), 5 
and 14, respectively, employed fMRI, the most widely available 
modality for imaging the ACC in depressed patients. Since these 
publications, a number of further fMRI studies have been con-
ducted, including a study by our group in which we reported 
that neural changes in response to an emotional processing 
task after 1 week of treatment with the selective serotonin reup-
take inhibitor (SSRI) escitalopram predicted clinical outcome 
after 6 weeks of treatment in a group of 32 depressed patients 
(Godlewska et  al., 2016). The present report concerns baseline 
(pretreatment) neural responses of this patient group to a dif-
ferent emotional task that employed masked faces as “implicit” 
(nonconscious) stimuli and their potential to act as predictors of 
subsequent response to escitalopram.
Interestingly, a similar implicit task was employed in a recent 
fMRI investigation, which also found a correlation between 
pretreatment activity in pgACC during the emotional process-
ing task and the subsequent response to 8 weeks of treatment 
with the SSRI sertraline in 10 unmedicated patients (Victor et al. 
2013). This study was designed to assess whether the results 
can be replicated in a larger group, allowing for a categorical 
classification of patients into responders and nonresponders. 
A similar task was used based on the concept that structures 
involved in rapid, nonconscious stimulus processing may be 
particularly reactive to masked stimuli and sensitive to depres-
sion (Victor et al. 2010, 2013, 2017).
The aim of the present study was to test this hypothesis that 
increased pgACC to masked sad facial expressions at baseline 
would predict later treatment response and provide an initial 
estimate of the degree to which this effect was able to predict 
treatment response at the level of the individual patient, using a 
leave-one-out (LOO) validation process.
Methods
Participants
Thirty-nine patients with major depression consented to take 
part in the study. Thirty-two (18F:14M) completed the fMRI scan 
and the 6-week period of escitalopram treatment (see Table 1 for 
demographic information). In the remaining 7 patients, relevant 
data were not available at the end of the treatment period (4 
patients dropped out before the 6-week assessment, and scan-
ning data from a further 3 patients were not available due to tech-
nical issues). All participants were assessed with the Structured 
Clinical Interview for DSM-IV (Spitzer et al., 1995) for the pres-
ence of current and past psychiatric disorders. The depressed 
patients met criteria for a primary diagnosis of major depres-
sive disorder; exclusion criteria were psychosis or substance 
dependence as defined by DSM-IV, a clinically significant risk of 
suicidal behavior, contraindications to escitalopram treatment 
or treatment with psychotropic medication <3 weeks before the 
study (5 weeks for fluoxetine), major somatic or neurological 
disorders, pregnancy or breast-feeding, any contra-indications 
to MR imaging, or concurrent medication that could alter emo-
tional processing. All participants were right-handed. The study 
was approved by the Oxford Research Ethics Committee and all 
participants gave written informed consent.
Table 1. Demographic Information for Responders and Nonresponders to 6 Weeks Treatment with Escitalopram 
Responder
(n = 20)
Nonresponders
(n = 12)
Gender 10F/10M 8F/4M P = .358, χ2 = 0.847
Age at time of scan (years) 28.25 ± 2.64 28.75 ± 9.28 P = .886, t = 0.144
Baseline depression severity (HAM-D) 23.0 ± 1.1 23.67 ± 0.9 P = .687, t = 0.407
Baseline depression severity (BDI-I) 31.2 ± 1.5 33.1 ± 1.5 P = .420, t = 0.818
Baseline trait anxiety (STAI-T) 59.5 ± 1.9 63.2 ± 10.8 P = .298, t = 1.059
Duration of current episode (months) 4.5 ± 0.6 8.8 ± 2.6 P = .06, t = 1.992
Abbreviations: HAM-D, Hamilton Depression Rating Scale; BDI-I - Beck Depression Inventory I; STAI-T, Spielberger’s State-Trait Anxiety inven-
tory; F, females; M, males.
Presented as mean ± SE.
Significance Statement
Most patients with depression do not respond to the first treatment they try, and in many cases multiple attempts are necessary 
to relieve symptoms. The fact that depression affects about 20% of the population at least once in their lifetime means that this 
problem applies to a substantial number of individuals. The delay in finding effective treatment, often extending to months or 
years, translates into unnecessary personal suffering and burden. This burden could be lessened if there were tests indicating 
those patients who are unlikely to respond to first-line treatment and require higher intensity treatment from outset. This study, 
using functional imaging, has added to the growing body of evidence pointing at the pregenual anterior cingulate cortex as a 
reliable predictor of subsequent treatment response in depression. Such studies bring us closer to the application of biological 
markers to predict therapeutic response in clinical practice.
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Study Design and Drug Treatment
Following the baseline fMRI scan, patients received 10 mg esci-
talopram each morning for a period of 6 weeks without dose 
adjustment. Assessment of depressive severity and treatment 
response was made using the 17-item Hamilton Depression 
Rating Scale (HAM-D) (Hamilton, 1960), with anxiety being 
measured with Spielberger’s State-Trait Anxiety inventory 
(Spielberger, 1989) at baseline and week 6.  The fMRI assess-
ments were completed at the same time points. The current 
analysis focuses on how baseline differences in the function of 
pgACC were able to predict clinical response at week 6 of treat-
ment. After the 6-week duration of the study, all patients were 
offered treatment openly with escitalopram according to usual 
clinical practice. Clinical response to the SSRI was defined as a 
reduction in HAM-D of 50% or more from baseline after 6 weeks 
of treatment (Angst et al., 1993).
fMRI Data Acquisition
fMRI data were acquired on a 3T Siemens TIM TRIO (Siemens 
AG). Data were acquired with a voxel resolution of 3 × 3 × 3mm, 
TR/TE/FA = 2000 milliseconds/28 milliseconds/89o. A total of 256 
volumes were acquired in an experiment lasting 6 minutes. T1-
weighted structural images were acquired using a magnetiza-
tion prepared rapid acquisition by gradient echo sequence with 
a voxel resolution 1.0 × 1.0 × 1.0 mm on a 208 × 256 × 200 grid, TE/
TI/TR = 4.68/900/2040 magnetization prepared rapid acquisition 
by gradient echo sequence. To monitor cardiac and respira-
tory processes, subjects wore a pulse oximeter and respiratory 
bellows.
fMRI Experimental Task
During fMRI scanning, participants completed a backward mask-
ing task. This task consisted of viewing pairs of faces paired in 
such a way that the first face, expressing sad, happy, or neutral 
emotion, was shown for 30 milliseconds and then immediately 
“masked” by another face of neutral expression, shown for 70 
milliseconds; this procedure has been shown to interfere with 
explicit perception of the first face (Victor et al. 2010). After each 
pair of faces was presented for 100 milliseconds in total, par-
ticipants were asked to report the gender of the face via an MRI 
compatible key pad; the gender of both faces was the same. Each 
participant was shown 4 sad blocks, 4 happy blocks, and 9 neu-
tral blocks, which were interleaved with sad and happy blocks 
(N-S-N-H-N-S-N-H-N or N-H-N-S-N-H-N-S-N). Between each 
block, there was a 10-second block of a baseline fixation cross.
fMRI Preprocessing and Statistical Analysis
Functional MRI data were preprocessed and analyzed using 
FMRIB software library  (FSL) (Jenkinson et  al. 2012). Briefly, 
motion correction was applied using a rigid body registration to 
the central volume; brain matter was segmented from nonbrain 
using a mesh deformation approach. Gaussian spatial smooth-
ing was applied with a full-width half maximum of 5 mm; high-
pass temporal filtering was applied using a Gaussian-weighted 
running lines filter, with a 3-dB cut-off of 120 seconds.
A general linear model was fitted in prewhitened data space. 
Three explanatory variables (plus their temporal derivatives) 
were modelled: sad faces, happy faces, and neutral faces. All 
explanatory variables were convolved with a default haemody-
namic response function (Gamma function, delay = 6 seconds, 
standard deviation = 3 seconds)and filtered by the same high-
pass filter as the data. The impact of physiological noise on 
the BOLD signal was reduced using the Physiological Noise 
Modelling tool of FSL. Pulse oximetry and respiratory bellows 
data were processed by Physiological Noise Modelling to create 
33 nuisance regressors, which were added to the first-level fMRI 
model. The full model was simultaneously regressed against the 
BOLD data, giving the best-fitting amplitudes for each explana-
tory variable while accounting for the physiological noise.
The task contrast of interest in this study was the relative 
activation of sad vs happy faces. The degree to which the change 
in neural activity in this contrast predicted participants’ clini-
cal response on the HAM-D to medication over 6 weeks was 
tested using a 2-level analysis. The first level consisted of the 
sad vs happy contrast maps, as described above, calculated for 
each depressed subject. Second-level, between-subject, random 
effects analysis assessed whether this change in neural activity 
differed between depressed patients who went on to respond to 
the medication and those who did not. Baseline HAM-D score 
was included as a regressor in the second-level analysis to 
account for the potential influence of initial depression severity 
effects on overall clinical response (NB baseline HAM-D score did 
not differ between the 2 groups, responders and nonresponders, 
Table 1, and equivalent results were obtained when the analysis 
was run without this covariate; supplemental Table 4).
The mask for the ACC as a priori region of interest (ROI) was 
derived from the Harvard-Oxford Cortical Anatomical Atlas and 
used in small volume correction analysis (SVC; clusters deter-
mined by Z > 2.3 and a (corrected) cluster significance threshold 
of P = .05). The mask included 1531 voxels. The results of group-
level whole-brain analyses were corrected using cluster-based 
thresholding with a height threshold of Z > 2·3 and a (whole-
brain corrected) spatial extent threshold of P = .05.
Additional analysis was performed with randomized, FSL’s 
nonparametric tool using Threshold-Free Cluster Enhancement 
thresholding approach with baseline HAMD as a nuisance vari-
able. This allowed for nonparametric permutation-based infer-
ence without a predefined arbitrary threshold, reducing the 
likelihood of false positive results. 5.000 permutations were 
performed.
Predictive Analysis
In addition to the analysis described above in which participant 
groups were defined based on future response to treatment, we 
were also interested in whether activity of the ACC could be 
used to predict response for individual patients. This was done 
using a LOO approach in which training and testing data were 
kept completely separate. This analysis involved firstly defining 
a cluster of voxels in which activity was greater for respond-
ers than nonresponders to the sad-happy contrast within the 
ACC (NB the cluster was defined using Z > 2.3 and P < .05 with 
a structural ROI based on the Harvard-Oxford Cortical Atlas) 
using just the training data (i.e., data from all but 1 participant). 
Secondly, mean activity was extracted within this cluster for 
all participants and the data from the training sample used to 
generate a receiver operator characteristic curve. Lastly, a cut-off 
was defined from the receiver operator characteristic curve of 
the training data as the point furthest from the leading diag-
onal and the held-out participant classified as a responder or 
nonresponder based on this cut-off. Note that this analysis was 
repeated for every participant and resulted in different clusters 
of voxels used in each classification as well as different cut-offs 
for the classification. This analysis provides an initial estimate 
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of the ability of activity within the ACC to predict response at 
the level of the individual patient.
Results
Clinical and Demographic Data
After 6 weeks’ escitalopram treatment, 20 of 32 patients (62%) 
were classified as responders. There were no differences 
between responders and nonresponders in terms of gender, age, 
baseline depression severity, baseline trait anxiety, or duration 
of current episode (Table 1).
fMRI Data
ROI Analysis—We performed SVC-corrected analysis of pgACC. 
In line with our hypothesis, we found an increased fMRI response 
to sad vs happy faces in the group of patients who after 6 weeks 
responded to treatment compared with those who did not, both 
with and without controlling for baseline depression HAMD 
severity (family wise error [few]-corrected P < .05, SVC; 248 voxels, 
Z-value of the peak voxel 3.48, P = .005). Exploring each emotion 
separately vs baseline showed that nonresponders had numeri-
cally greater pgACC responses to both sad and happy faces, with 
the majority of the difference between the 2 groups apparently 
being due to altered responses to happy faces (Figure 1).
While we used an ACC mask based on the commonly used 
Harvard-Oxford Cortical Anatomical Atlas, the part of the clus-
ter identified can be described as located in the anterior midcin-
gulate cortex. An additional analysis with a 600-voxel mask 
consisting only of volumes anterior to the genu of corpus callo-
sum was run, and a similar response to that reported above was 
observed in a cluster of 123 voxels, the part of the original clus-
ter corresponding to strictly defined ACC (results not reported).
Figure 1. Baseline differences in neural response (percent signal change) in the pregenual anterior cingulate cortex (pgACC) region of interest (ROI) in response to sad 
vs happy facial expressions differentiated between responders and nonresponders to 6 weeks of treatment with escitalopram. The figure represents (a) results of small 
volume correction (SVC) analysis in the anterior cingulate cortex (ACC) using a parametric approach (Gaussian Random Field Theory); (b) extracted signal change in 
the identified cluster (mean and standard error); (c) results of SVC-corrected analysis in the anterior cingulate cortex using a nonparametric approach (Threshold-Free 
Cluster Enhancement). Analysis was thresholded at Z = 2.3 and cluster-corrected with a family wise error (FWE) P < .05. Baseline 17-item Hamilton Depression Rating 
Scale (HAM-D) scores were entered as a covariate.
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Whole-Brain Analysis—The exploratory analysis at the 
whole-brain level using a parametric approach revealed a 
greater activation to sad vs happy faces in treatment respond-
ers compared with nonresponders across a network of struc-
tures including ACC, paracingulate, right and left caudate, right 
thalamus and a small part of left thalamus, left putamen, and 
a small portion of fronto-occipital cortex, both when control-
ling for baseline depression HAMD severity and not (P < .05, 
FWE corrected; Figure 2). For details on functional clusters, see 
Table 2. The Threshold-Free Cluster Enhancement nonparamet-
ric method revealed a similar increased activation in response 
to sad vs happy faces in treatment responders vs nonresponders 
across a network of structures, with the peak in the ACC and 
inclusing paracingulate gyrus, bilateral middle frontal gyrus, 
bilateral frontal orbital cortex, frontal pole, bilateral thalamus, 
and left insula.
Prospective analysis allowed predicting classification into 
responders and nonresponders with moderate accuracy of 
71.875%. The center of mass of the clusters is shown in Figure 2. 
A histogram of cut-off scores and confusion matrix are shown in 
Figures 3 and 4, respectively.
Discussion
Our study showed that pretreatment neural activation of pgACC 
in response to subliminal emotional information was predictive 
of short-term (6 weeks) therapeutic response to an SSRI esci-
talopram in patients with depression. A  similar pattern was 
observed in a network of cortical and limbic areas associated 
with depression. Our findings support the body of evidence 
pointing to the ACC as currently the most reliable marker of 
response to various modes of treatment for depression and 
show its role in response to emotional information presented 
below the level of conscious awareness.
Our findings are consistent with meta-analyses by Pizzagalli 
(2011) and Fu et al. (2013) and other more recent studies impli-
cating the pgACC as the region in which baseline function is 
linked to future response to antidepressant treatment (e.g., Roy 
et al., 2010; Kozel et al., 2011; Miller et al., 2013; Victor et al., 2013; 
Dichter et al., 2015; Cullen et al., 2016; Vai et al., 2016; Crane et al., 
2017; Klumpp et  al., 2017). Of recent investigations, the study 
by Victor et al. (2013) was of particular relevance to our inves-
tigation because it also employed an implicit emotional task 
Figure 2. Baseline differences in neural response (percent signal change) at the whole-brain level in response to sad vs happy facial expressions differentiated between 
responders and nonresponders to 6 weeks of treatment with escitalopram. The figure represents (a) results of the exploratory analysis at the whole-brain level using a 
parametric approach (Gaussian Random Field Theory); (b) extracted signal change in the identified clusters (mean and SE); (c) results of the exploratory analysis at the 
whole-brain level using a nonparametric approach (Threshold-Free Cluster Enhancement). Details of the clusters can be found in Table 2. Analysis was thresholded at 
Z = 2.3 and cluster-corrected with a FWE P < .05. ACC, anterior cingulate cortex; FOC fronto-orbital cortex; FWE, family wise error. Baseline 17-item Hamilton Depression 
Rating Scale (HAM-D) scores were entered as a covariate.
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based on presentation of masked sad and happy faces. Victor 
et al. (2013) found a decrease in the haemodynamic response in 
the pgACC to the contrast of masked sad vs happy faces after 
8 weeks of treatment with another SSRI, sertraline, in 10 par-
ticipants with depression. They also found a positive correlation 
between symptomatic improvement in depression ratings and 
baseline pgACC activation to masked sad vs happy faces, impli-
cating pgACC in antidepressant response and its prediction. 
Studying a larger group of participants and using a similar task 
based on masked presentation of emotions, we were also able to 
show differential baseline pretreatment activity of the pgACC in 
treatment responders and nonresponders.
The pgACC is a part of an extended medial prefrontal net-
work, uniquely positioned with connections both to the amyg-
dala and PFC (Drevets 2001, Mayberg 2003). It plays an important 
role in emotion appraisal and regulation, evaluation of the 
salience of emotional stimuli, and emotion-related learning 
(Stevens et  al. 2011), the processes that are dysregulated in 
depression and improve with successful treatment. Since the 
seminal publication by Mayberg et  al. (1997), a wide range of 
research has consistently implicated pgACC as a brain region 
linked to treatment response.
Increased activity in the pgACC was typically found to 
be predictive of better treatment outcomes regardless of 
the modality used to measure ACC activity (fMRI, positron 
emission tomography (PET), Magnetoencephalography, and 
Electroencephalography), design (i.e., resting state or task-
based), and form of treatment employed (pharmacotherapy, 
transcranial magnetic stimulation, CBT, and sleep deprivation), 
as reviewed by Pizzagalli in 2011. Although only 5 of 23 studies 
included in this review were fMRI studies, other fMRI studies 
have since been published, including a meta-analysis by Fu et al. 
(2013) of 20 functional neuroimaging papers (14 fMRI studies, 10 
using various emotional processing tasks, 4 using nonemotional 
tasks, and 6 PET studies in resting state conditions). Similar to 
Pizzagalli’s paper (2011), this meta-analysis showed a higher 
likelihood of improvement in response both to pharmacother-
apy (14 included studies) or CBT (6 included papers) in patients 
with increased pretreatment activation in the pgACC as well as 
in subgenual and medial prefrontal cortices.
Since the publication of these meta-analyses, other stud-
ies, including ours (Godlewska et al., 2016), have added to the 
relatively consistent body of evidence suggesting increased 
ACC activation during emotional processing and resting state 
as a putative marker of good clinical response to treatment. 
Although the results are not unequivocal (Fu et  al., 2013) and 
are still some way off routine clinical application, currently the 
pgACC is one of the most, if not the most, promising pretreat-
ment imaging biomarkers of antidepressant response, because 
of both its postulated role in the pathophysiology of depression 
and the consistency of reports on its role in treatment response 
prediction.
In addition to the pgACC, our exploratory whole-brain 
analysis revealed a number of other regions showing a simi-
lar neural response to the employed task, that is, increased 
activity in response to sad vs happy facial expressions allowed 
Table 2. Prediction of Clinical Response after 6 Weeks of Escitalopram Treatment from Baseline Differences in Pretreatment Neural Response 
to Sad Compared with Happy Facial Expressions 
Cluster content
Peak voxel
MNI Coordinates
Cluster size, 
voxels Z-value P valuex y Z
Parametric approach (Gaussian Random Field Theory)
Cluster A: L middle frontal gyrus, ACC, paracingulate gyrus, R 
caudate, R thalamus leaking into L thalamus
-28 32 28 2173 3.66 .000000238
Cluster A: local maxima 22 12 16 3.59
24 -28 26 3.59
22 16 22 3.54
30 26 24 3.53
-6 30 20 3.48
Cluster B: Frontal orbital cortex, L putamen, L caudate, L 
accumbens
-32 34 -4 544 3.68 .0276
Cluster B: local maxima -18 22 -4 3.37
-28 40 -4 3.24
-22 48 -8 3.04
-24 12 -18 3.03
-22 44 -8 3.00
Cluster C: ACC, paracingulate gyrus 26 36 0 523 3.7 .0336
Cluster C: local maxima 16 36 -4 3.37
18 42 2 3.27
34 42 -2 3.04
20 26 10 3.03
20 42 -8 2.89
Nonparametric approach (Threshold-Free Cluster Enhancement)
Cluster: ACC, paracingulate gyrus, bilateral middle frontal gyrus, 
bilateral frontal orbital cortex, frontal pole, bilateral thalamus, 
left insula
-4 30 16 6617 4.99 <.05
Abbreviations: ACC, anterior cingulate cortex.
The table shows functional clusters identified by the exploratory analysis at the whole brain level. Please refer to Figure 1 for more details.
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differentiation between future treatment responders and non-
responders. These regions included paracingulate cortex, thal-
amus, caudate, putamen, nucleus accumbens, and orbitofrontal 
cortex (Figure 2). These structures are part of networks involved 
in the processing of emotionally valenced information and 
reward, and their disruption has been hypothesized to contrib-
ute to low mood and anhedonia, core symptoms of depression 
(Graham et al., 2013; Fettes et al. 2017).
The basal ganglia regions identified in this study (caud-
ate nucleus, putamen, and nucleus accumbens) are involved 
in reward processing and form connections with the ACC and 
thalamus, with the ACC-basal ganglia-thalamus loop suggested 
to monitor unexpected events and to recruit adaptive mecha-
nisms as required (Maia and Frank, 2011). Our results suggest 
that the pgACC is clearly a node in a distributed network of 
regions involved in processing of emotionally salient informa-
tion. It is likely that differences in the function of this network, 
rather than solely in the pgACC function, are associated with 
antidepressant response.
The period of time when response to antidepressants was 
assessed, 6 weeks into treatment, was chosen to be consistent 
with common clinical practice. Six weeks is around the time 
when clinicians often make decisions as to whether to continue 
treatment unchanged, adjust the dose, or switch to a different 
medication, and is in line with current treatment guidelines 
(NICE Pathways, 2017). A reliable marker of this early response 
could potentially save a patient from unnecessary weeks of 
delay in finding treatment they respond to. Treatment response 
was defined as baseline at least 50% decrease in HAMD scores 
as this definition, although somehow arbitrary, is a commonly 
used measure (Angst et al., 1993).
To be clinically useful, a biomarker of treatment response 
needs to classify patients into responders and nonresponders 
Figure 3. Confusion plot. Green squares represent correctly classified cases: TP, true positives; TN, true negatives, the number of correct classifications by the trained 
network, percentage of all cases they represent. Red squares represent incorrectly classified cases: FP, false positives, FN, false negatives, the number of correct clas-
sifications by the trained network, percentage of all cases they represent. The blue square represents the percentage of correct and incorrect classifications. The first 
row represents predicted nonresponders, of whom 61.5% were classified correctly and 38.5% incorrectly. The second row represents predicted responders, of whom 
78.9% were classified correctly and 21.1% incorrectly. Of 12 nonresponders, 66.7% were correctly predicted as nonresponders and 33.3% were predicted as responders. 
Of 20 responders, 75% were correctly classified as responders and 25% were classified as nonresponders. Overall, 71.9% of the predictions were correct and 28.1% cases 
were classified incorrectly.
Figure 4. Histogram of the cut-off scores used in the classifier.
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with reasonable accuracy; so far, no known biomarker has been 
consistently replicated in subsequent studies with accuracy 
high enough to be deemed useful in clinical practice (Fu and 
Costafreda, 2013). Predictive analysis performed in this study 
allowed classification of participants into responders and non-
responders with an accuracy of 71.9%, which differs from a 
probability of 0.5 with a P of .02. However, caution is required 
with this estimate of accuracy as LOO approaches to validation, 
as used in the current study, will tend to overestimate classi-
fier accuracy compared with validation in a fully held-out sam-
ple (Hastie et al., 2009). This limitation is related to a number of 
statistical and methodological aspects of LOO procedures. First, 
clinically relevant classification requires between-dataset gen-
eralization of classification performance (predictions need to 
be made on completely unseen data), which is not accounted 
for by LOO procedures based only on within-dataset perform-
ance. Second, individual data points in LOO procedures will be 
used in all but one training sets, meaning that influential (e.g., 
outlying) data points can have exaggerated effects on classifier 
performance across training sets, which can skew estimates 
of classifier performance. As a result, it will be essential to test 
whether pgACC activity is able to meaningfully predict treat-
ment response in a fully held-out sample of patients.
A number of studies have used machine learning approaches 
to derive classifiers from fMRI data. These approaches tend 
to have many more predictors (i.e., voxels) than data points 
(patients) and are also difficult to interpret from a mechanistic 
perspective as they incorporate complex interactions between 
predictors. In our study, we used a very simple, univariate out-
come from a prespecified region, which provides a mechanisti-
cally transparent predictor. Clearly, however, it may be possible 
to improve on the predictive performance reported here by 
employing a multivariate approach to combine different fea-
tures in the classifier. Additionally, there may well be alterna-
tive methods for deriving the predictive features from the fMRI 
data. In the current study, we used mean signal change from 
clusters, defined in the training set. The clusters were defined 
on the basis of anatomical location (within the ACC) and statis-
tical significance. It may be that using alternative methods for 
cluster/feature definition (e.g., changing the level of statistical 
significance for the cluster or relaxing the anatomical specifica-
tion) would increase the information contained in the cluster 
and improve classification performance.
The ACC response seems to predict positive therapeutic 
outcome to many different kinds of treatment (Pizzagalli, 2011; 
Fu et al., 2013). Therefore, it does not currently point to selec-
tion of a particular antidepressant treatment modality or psy-
chotherapy in preference to pharmacotherapy. Equally, it does 
not suggest an alternative treatment regime for patients with 
low ACC responsivity who, at the moment, are predicted to do 
less well with various kinds of antidepressant therapies. At the 
same time, it may play an important role in identifying people 
with poor prognosis who can be given more intensive treatment 
from the start, leading to improving overall time to remission. It 
might also serve as a marker of efficacy when testing new drugs 
for antidepressant properties.
Our study has some limitations. The main limitation is 
the small size of the group. The group itself was composed of 
carefully chosen drug-free patients, yet increasing the number 
would increase the power and allow for more complex analyses 
combining different putative markers, an approach aiming at 
increasing accuracy of classification. The lack of a control group 
may be considered as another limitation; however, the aim of 
the current study was to explore markers of treatment response 
prediction, for which a group of healthy volunteers or placebo-
treated patients is not strictly necessary. One limitation reflects 
a general question of feasibility of using imaging biomarkers 
in clinical settings, as scanning is not yet widely available and 
the procedure is still relatively costly. However, if the prediction 
using imaging biomarkers becomes sufficiently accurate, ben-
efits including a decrease of depression burden on both indi-
viduals and society achieved through more efficient therapeutic 
processes could make it cost effective.
In summary, our study has shown that pretreatment 
pgACC activity is predictive of response to antidepressant 
treatment after 6 weeks. It has also identified other brain 
regions where differential activity in response to an implicit 
emotional task had a similar predictive value. Our study adds 
to the growing body of evidence pointing at the pgACC as a 
reliable predictor of subsequent treatment response to a vari-
ety of therapeutic approaches to depression. Although the 
accuracy of classification in our study was moderate, it was 
higher than by chance. Given that the pgACC pretreatment 
function as response prediction marker has been the most 
consistently replicated neuroimaging finding, it makes it the 
most promising putative fMRI-based treatment response bio-
marker. To understand better the potential of pgACC imag-
ing in this context, future studies are needed, on large groups 
and in patients at different stages of depression, employing 
machine learning approaches to combine pgACC effect with 
other neuroimaging and/or behavioral measures to increase 
classification accuracy.
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